Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ozlem Belen
Observed names:
O. Belen,
Ozlem A. Belen
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0009-0009-5567-3193
Observed ORCID:
0009-0009-5567-3193
OpenAlex ID:
A5013131719
Summary of the US FDA Approval of Belatacept
2012
·
P. Archdeacon
, C. Dixon
, et al.
·
American Journal of Transplantation
·
123
Summary of 2017 FDA Public Workshop: Antibody-mediated Rejection in Kidney Transplantation
2018
·
Ergun Velidedeoglu
, Marc W. Cavaillé-Coll
, et al.
·
Transplantation
·
78
Meeting report: FDA public meeting on patient-focused drug development and medication adherence in solid organ transplant patients
2017
·
Robert Ettenger
, Renata Albrecht
, et al.
·
American Journal of Transplantation
·
58
Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID ‐19 Under the Emergency Use Authorization
2024
·
Qi Liu
, Raj Nair
, et al.
·
Clinical Pharmacology & Therapeutics
·
19
PDF
The Role of Patient-reported Outcomes and Medication Adherence Assessment in Patient-focused Drug Development for Solid Organ Transplantation
2021
·
Stephen R. Karpen
, Amanda Klein
, et al.
·
Transplantation
·
12
Approval of Mycophenolate Mofetil for Prophylaxis of Organ Rejection in Pediatric Recipients of Heart or Liver Transplants: A Regulatory Perspective
2024
·
Amer Al‐Khouja
, Nadia Chaudhri
, et al.
·
Clinical Pharmacology & Therapeutics
·
8
Approval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective
2025
·
Lei He
, Da Zhang
, et al.
·
The Journal of Clinical Pharmacology
·
5
PDF
Show more works
View as search
Works count:
7
Citation count:
303
H-index:
6
I10-index:
5
Year
Topic
Type